Skip to main navigation
Skip to Content
logo
  • Overview
  • Stock Information
    • Stock Quote and Chart
    • Historical Price Lookup
    • IRS Form 8937
  • SEC Filings
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
    • Investor FAQs
  • Company
    • Press Releases
    • Events & Presentations
    • Pipeline
  • Contact Us
  • ImmunityBio.com

Press Releases

Press Releases

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
Feb 16, 2023
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
Feb 15, 2023
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
Jan 19, 2023

IR Tools

Print Page
RSS Feeds
Email Alerts
logo
© 2023 ImmunityBio, Inc. All Rights Reserved.
A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘Conkwest’, ‘haNK’, ‘taNK’, ‘vaNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Neukosome’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Infacell’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, Inc.

Anktiva is a trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons